Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 3/2015

01-03-2015 | Sarcoma (SH Okuno, Section Editor)

Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors

Authors: Diana Bradford, MD, AeRang Kim, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 3/2015

Login to get access

Opinion statement

Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas characterized by high risk of local recurrence and distant metastasis. The only known curative therapy is complete resection. Adjuvant radiation is recommended for larger lesions or those with more aggressive histology. Given the dismal prognosis in tumors that cannot be cured by surgery alone and the lack of systemic therapy with proven benefit, targeted therapies based on knowledge of activation of the Ras pathway and downstream effectors have been trialed in MPNST, thus far without proven benefit. However, novel or combination therapies based on recent preclinical advances are highly desirable and are the subject of ongoing clinical trials.
Literature
1.
Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009;11(4):322–8.PubMedCrossRef
2.
Ducatman BS et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57(10):2006–21.PubMedCrossRef
3.
4.•
Meany H, Widemann BC, Ratner N. Malignant peripheral nerve sheath tumors: prognostic and diagnostic markers and therapeutic targets. In: Neurofibromatosis Type 1. Berlin: Springer; 2012. p. 445–67. An updated overall review of MPNST biology and potential targets.CrossRef
5.
Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104(4):593–604.PubMedCrossRef
6.
Carli M et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23(33):8422–30.PubMedCrossRef
7.•
Stucky CC et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878–85. Recent, large, single-institution retrospective review to evaluate prognostic variables in this rare tumor type.PubMedCrossRef
8.
Beert E et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosom Cancer. 2011;50(12):1021–32.PubMedCrossRef
9.
Kourea HP et al. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol. 1999;155(6):1855–60.PubMedCentralPubMedCrossRef
10.
Nielsen GP et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999;155(6):1879–84.PubMedCentralPubMedCrossRef
11.
Wong WW et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42(2):351–60.PubMedCrossRef
12.
Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791–6.PubMedCrossRef
13.•
Kolberg M. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15(2):135–47. This analysis examines survival in MPNST and demonstrates improved survival NF1-associated MPNST compared to sporadic tumors, contrary to historical data.PubMedCentralPubMedCrossRef
14.
Johannessen CM et al. TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008;18(1):56–62.PubMedCrossRef
15.•
Endo M et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19(2):450–61. This study examined activation profiles of the AKT/mTOR and MAPK pathways in tumor specimens and correlated these results with prognosis. The study also assessed the in vitro activity of everolimus, which demonstrated antitumor activity in MPNST cell lines, providing insight into potential therapeutic pathways.PubMedCrossRef
16.
Bottillo I et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol. 2009;217(5):693–701.PubMedCrossRef
17.
Pasmant E et al. Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients. Mol Med. 2011;17(1–2):79–87.PubMedCentralPubMed
18.
Watson MA et al. Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 2004;14(3):297–303.PubMedCrossRef
19.
Brekke HR et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol. 2010;28(9):1573–82.PubMedCrossRef
20.
Ferner R et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry. 2000;68(3):353–7.PubMedCentralPubMedCrossRef
21.
Benz MR et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010;116(2):451–8.PubMedCentralPubMedCrossRef
22.
Ferner R et al. [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19(2):390–4.PubMedCrossRef
23.
Bensaid BGF, Mognetti T, Galoisy-Guibal L, Pinson S, Drouet A, Combemale P. Utility of 18 FDG positron emission tomography in detection of sarcomatous transformation in neurofibromatosis type 1. Ann Dermatol Venereol. 2007;134(10 Pt 1):735–41.PubMedCrossRef
24.
Bredella MA et al. Value of PET in the assessment of patients with neurofibromatosis Type 1. Am J Roentgenol. 2007;189(4):928–35.CrossRef
25.
Scaife CL, Pisters PW. Combined-modality treatment of localized soft tissue sarcomas of the extremities. Surg Oncol Clin N Am. 2003;12(2):355–68.PubMedCrossRef
26.
Pisters PW et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.PubMed
27.
Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2008;19(4):533–43. v.PubMedCrossRef
28.
Yang JC et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.PubMed
29.
Kahn J et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014;4:324.PubMedCentralPubMedCrossRef
30.
Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573–7.PubMed
31.
Widemann B, et al. SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). J Clin Oncol. 2013; 31 (suppl; abstr 10522).
32.
Raney B et al. Treatment of children with neurogenic sarcoma experience at the children's hospital of Philadelphia, 1958–1984. Cancer. 1987;59(1):1–5.PubMedCrossRef
33.
Li H et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002;62(15):4507–13.PubMed
34.
35.
Chugh R et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27(19):3148–53.PubMedCrossRef
36.
Albritton K, et al. Phase II trial of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumor (MPNST). J Clin Oncol. 2006; 24 (suppl; abstr 9518).
37.
Schuetze S, et al. Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. J Clin Oncol. 2010; 28(15s (suppl; abstr 10009)).
38.
Johansson G et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008;7(5):1237–45.PubMedCentralPubMedCrossRef
39.
Vogel KS et al. Mouse tumor model for neurofibromatosis Type 1. Science (New York, NY). 1999;286(5447):2176–9.CrossRef
40.
Cichowski K et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286(5447):2172–6.PubMedCrossRef
41.
42.•
De Raedt T et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011;20(3):400–13. This study demonstrated that promotion of proteotoxic stress on the endoplasmic reticulum via Hsp90 inhibition in combination with mTOR inhibition resulted in irreparable damage to mitochondria and ER, which correlated with dramatic tumor shrinkage in a transgenic MPNST mouse model. This promising finding led to the rapid development of SARC023, a Phase I/II study of gantespib and sirolimus in MPNST.PubMedCentralPubMedCrossRef
43.
Kim A, et al. SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol. 2014; 32(5s (suppl; abstr TPS10603)).
44.•
Malone CF et al. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov. 2014;4(9):1062–73. This study demonstrated that combined inhibition of mTOR and MEK induce tumor regression in vivo. In addition, 18FDG-PET was identified as a potential real-time indicator for target inhibition by these agents, and thus identifying a potential imaging biomarker for evaluation in clinical trials.PubMedCentralPubMedCrossRef
Metadata
Title
Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors
Authors
Diana Bradford, MD
AeRang Kim, MD, PhD
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 3/2015
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-015-0328-6
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits